Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR +/ HER2 – Advanced Breast Cancer

The Oncologist ◽

10.1002/onco.13866 ◽

2021 ◽

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Survival Benefit ◽

Advanced Breast ◽

Overall Survival Benefit

Download Full-text

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

Cancer Treatment Reviews ◽

10.1016/j.ctrv.2009.10.006 ◽

2010 ◽

Vol 36 (1) ◽

pp. 69-74 ◽

Author(s):

Davide Mauri ◽

Konstantinos Kamposioras ◽

Lamprini Tsali ◽

Magdalini Bristianou ◽

Antonis Valachis ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Survival Benefit ◽

Meta Analysis ◽

Advanced Breast ◽

Overall Survival Benefit

Download Full-text

Palbociclib Plus Fulvestrant Maintains Long‐Term Overall Survival Benefit in HR +/ HER2 – Advanced Breast Cancer

The Oncologist ◽

10.1002/onco.13864 ◽

2021 ◽

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Survival Benefit ◽

Advanced Breast ◽

Overall Survival Benefit

Download Full-text

A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05626-1 ◽

2020 ◽

Vol 181 (1) ◽

pp. 211-220 ◽

Author(s):

J. Watanabe ◽

M. Saito ◽

Y. Horimoto ◽

S. Nakamoto

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Cancer Patients ◽

Lymphocyte Count ◽

Survival Benefit ◽

Absolute Lymphocyte Count ◽

Breast Cancer Patients ◽

Institutional Experience ◽

Overall Survival Benefit

Download Full-text

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

Hormone Receptor Positive

Download Full-text

Faculty Opinions recommendation of Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.738775672.793581181 ◽

2020 ◽

Author(s):

Jason S Carroll

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Dose Escalation ◽

Advanced Breast ◽

Download Full-text

Clinical Trial of Letrozole (femara) versus Aminoglutethimide in Postmenopausal Women with Advanced Breast Cancer

The Chinese-German Journal of Clinical Oncology ◽

10.1007/s10330-005-0387-4 ◽

2005 ◽

Vol 4 (6) ◽

pp. 338-340

Author(s):

Xiaoqing LIU ◽

Santai SONG ◽

Zefei JIANG ◽

Weilian LI ◽

Weixia WANG ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Advanced Breast

Download Full-text

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

Clinical & Translational Oncology ◽

10.1007/s12094-017-1797-9 ◽

2017 ◽

Vol 20 (7) ◽

pp. 862-869 ◽

Author(s):

I. Blancas ◽

M. Fontanillas ◽

V. Conde ◽

J. Lao ◽

E. Martínez ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Practice ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Routine Clinical Practice ◽

Advanced Breast

Download Full-text

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽

Hormone Receptor Positive

Download Full-text

CDK4/6 Inhibitors Boost Overall Survival in HR-Positive, HER2-Negative Advanced Breast Cancer

Default Digital Object Group ◽

10.1200/adn.21.200595 ◽

2021 ◽

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Advanced Breast

Download Full-text

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Journal of Bone Oncology ◽

10.1016/j.jbo.2018.09.010 ◽

2019 ◽

Vol 14 ◽

pp. 100199 ◽

Author(s):

Peyman Hadji ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M. Kurbacher ◽

Frederik Marmé ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Mammalian Target Of Rapamycin ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Download Full-text